23andMe announces exploration of strategic alternatives

The Special Committee of the board of 23andMe (ME) Holding Co. announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a possible sale of the company, business combination, sale of all or part of the company’s assets, licensing of assets, restructuring, or other strategic action. The board of 23andMe previously formed the Special Committee, which is comprised of independent directors, to review strategic alternatives that may be available to 23andMe. The Special Committee has engaged Moelis & Company as its financial advisor and Goodwin Procter LLP as its legal advisor. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions. 23andMe does not expect to disclose or provide an update concerning developments related to this process until the company enters into definitive agreements or arrangements with respect to a transaction or otherwise determines that additional disclosure is appropriate or required by law.